Angiotensin receptor blockers following acute stroke
Denise H Rhoney1, Lynette R Moser
1Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 4820, USA. drhoney@wayne.edu
Abstract:
Elevated blood pressure during the acute stroke period is associated with poor neurologic outcomes; however, treating blood pressure in this setting remains controversial. Interest in modulating the renin-angiotensin system in this setting has gained momentum because of neurohormonal properties, which may provide benefits beyond blood pressure control. The Scandinavian Candesartan Acute Stroke Trial (SCAST) was recently published describing the effects of candesartan in patients with hypertension during the acute stroke period. This study shows that lowering blood pressure with an ARB for 7 days poststroke does not improve 6-month neurologic outcomes. This article provides a context for a continuing discussion regarding the role of blood pressure lowering in patients following acute stroke.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Acute Coronary Syndrome IV: Interprofessional Care

